IDH1 and central nervous system cancer: There are, however, heterogenous subsets within this IDH-wildtype astrocytoma group, which show longer median survival, with a handful of proposed genetic alterations responsible for the better prognosis, including amplification of MYB and BRAF V600E mutation, which have both been shown to correlate with longer OS in select grade II IDH-wildtype gliomas [132].